Top 10 Manufacturers of Pharmaceutical Intermediate CAS No. 573762-62-6 in 2025

Understanding tert-Butyl 6-cyano-2-oxindole-1-carboxylate (CAS No. 573762-62-6)

tert-Butyl 6-cyano-2-oxindole-1-carboxylate (CAS No. 573762-62-6) is a complex pharmaceutical intermediate featuring a cyano group and a protected oxindole scaffold. This compound plays a critical role in synthesizing kinase inhibitors, a class of targeted anticancer agents. Due to its specific structure, it is also useful in developing drugs that modulate cell signaling pathways and inflammation responses.

This intermediate’s stability, purity, and synthetic compatibility make it highly sought after in modern medicinal chemistry, particularly for creating small-molecule drugs used in oncology and autoimmune therapies.

Importance of tert-Butyl 6-cyano-2-oxindole-1-carboxylate in Drug Development

Targeted Oncology Therapies:

This intermediate is frequently used in synthesizing kinase inhibitors — targeted anticancer drugs that interfere with specific enzymes involved in tumor growth and proliferation.

Drug Safety and Efficacy:

With strict purity requirements, high-quality synthesis of this compound ensures fewer impurities in the final drug product, improving both safety and efficacy.

Synthetic Flexibility:

Its structure supports modifications, making it suitable for developing derivatives and analogs in various therapeutic classes beyond oncology, such as neurodegeneration and inflammation.

Global Regulatory Compliance:

As a critical part of the pharmaceutical supply chain, the production of tert-butyl 6-cyano-2-oxindole-1-carboxylate must comply with international standards such as GMP and ICH guidelines to ensure global market access.

Top 10 Manufacturers of CAS No. 573762-62-6

1. Lonza Group

• Location: Basel, Switzerland

• Overview: Lonza is a global leader in CDMO services, specializing in high-value pharmaceutical intermediates like tert-butyl 6-cyano-2-oxindole-1-carboxylate. Their oncology expertise and state-of-the-art facilities make them a trusted partner for complex synthesis.

• Specialty: Oncology and small-molecule CDMO services.

2. Wacker Chemie AG

• Location: Munich, Germany

• Overview: Wacker provides a broad range of chemical and pharmaceutical intermediates, including oxindole derivatives. Their advanced synthesis technologies ensure consistent quality for specialized intermediates.

• Specialty: Custom synthesis, process development, advanced intermediates.

3. Eastfine

• Location: Changzhou City, Jiangsu Province, China

• Overview: Eastfine is a key global manufacturer of pharmaceutical intermediates, offering consistent supply of CAS 573762-62-6 for clients developing kinase inhibitors. Known for quality, reliability, and GMP compliance, Eastfine is a preferred partner for cost-effective, high-purity intermediates.

• Specialty: Oncology intermediates, fine chemicals, global compliance.

4. Almac Group

• Location: Craigavon, United Kingdom

• Overview: Almac is a well-regarded CDMO offering synthesis and scale-up of challenging molecules like tert-butyl 6-cyano-2-oxindole-1-carboxylate. They serve biotech and pharmaceutical firms across North America and Europe.

• Specialty: GMP manufacturing, oncology-focused synthesis.

5. PharmAgra Labs

• Location: North Carolina, USA

• Overview: A boutique CDMO specializing in custom synthesis for early- to mid-phase drug development. PharmAgra is known for producing oxindole scaffolds and other complex heterocycles.

• Specialty: R&D-scale to pilot-scale synthesis of advanced intermediates.

6. Cambrex Corporation

• Location: East Rutherford, New Jersey, USA

• Overview: Cambrex focuses on small-molecule intermediates for branded and generic drugs. Their expertise includes scale-up and process optimization for complex intermediates like CAS 573762-62-6.

• Specialty: Scale-up of kinase inhibitor intermediates, regulatory support.

7. Evonik Industries

• Location: Essen, Germany

• Overview: Evonik manufactures a wide variety of pharmaceutical building blocks and intermediates, including protected oxindoles. Their sustainability and quality systems meet strict international standards.

• Specialty: High-performance intermediates and green synthesis technologies.

8. Syngene International

• Location: Bangalore, India

• Overview: Syngene provides integrated research and manufacturing services, producing advanced intermediates for oncology and autoimmune therapies. Their facilities are FDA- and EMA-audited.

• Specialty: Kinase inhibitor intermediates, custom synthesis.

9. Siegfried Holding AG

• Location: Zofingen, Switzerland

• Overview: Siegfried is a global contract manufacturer with strong capabilities in high-purity intermediates for small-molecule APIs. They offer cGMP manufacturing for complex intermediates used in clinical and commercial settings.

• Specialty: Oncology and inflammation intermediates.

10. Mylan Pharmaceuticals (Viatris)

• Location: Canonsburg, Pennsylvania, USA

• Overview: Mylan (now Viatris) is known for high-volume manufacturing of generics and APIs. They support synthesis of specialized intermediates such as CAS 573762-62-6 for oncology and chronic disease treatments.

• Specialty: Oncology intermediates for global generic markets.

Trends in the Pharmaceutical Intermediates Market

Rising Demand for Kinase Inhibitors:

As precision oncology advances, kinase inhibitors are dominating new drug pipelines. Intermediates like CAS 573762-62-6 are critical to this growth, enabling the synthesis of structurally complex molecules.

Custom Manufacturing Partnerships:

Companies are increasingly outsourcing synthesis of advanced intermediates to CDMOs like Eastfine, Lonza, and Almac, which offer tailored manufacturing solutions with regulatory support.

Green and Continuous Chemistry:

Environmental regulations are pushing manufacturers toward greener processes and continuous flow chemistry for improved sustainability and efficiency.

Regulatory Pressure on Quality Control:

To meet evolving FDA and EMA expectations, companies must implement enhanced analytical methods and strict in-process controls, especially for complex molecules like tert-butyl 6-cyano-2-oxindole-1-carboxylate.

Conclusion

CAS No. 573762-62-6 (tert-Butyl 6-cyano-2-oxindole-1-carboxylate) is a vital pharmaceutical intermediate in the synthesis of targeted anticancer drugs. Companies like Lonza, Wacker, and Eastfine are leading the way by delivering high-purity material that supports innovation in oncology and autoimmune therapeutics.

As drug pipelines grow more complex, demand for such intermediates will accelerate — placing a premium on technical expertise, regulatory readiness, and manufacturing scalability. The companies listed above are well-positioned to meet these evolving industry needs.